Reports Q4 revenue $54.14M, consensus $43.88M. “2024 represents our transformation into an innovative oncology company, culminating in the agreement to divest UDENYCA,” said Denny Lanfear, Coherus chairman and CEO. “In 2025, we will be sharply focused on maximizing the revenue potential for LOQTORZI while advancing the development of our pipeline, including our first-in-class IL-27 antagonist, casdozokitug, and our CCR8-targeting antibody, CHS-114, in combination with LOQTORZI.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRS:
Questions or Comments about the article? Write to editor@tipranks.com